Thermo Fisher (NYSE: TMO) holder Marc Casper plans another stock sale
Marc N. Casper, a holder in Thermo Fisher Scientific Inc. (TMO), plans to sell 10,000 shares of common stock, acquired via a stock option exercise, for cash on August 21, 2026. This proposed sale, valued at approximately $6.27 million, is detailed in a Rule 144 SEC filing. The filing also reports several previous sales by Marc N. Casper and Floral Park Associates Inc. within the last three months, totaling millions of dollars.
Agilent Stock Has A Catalyst Coming On August 26 That Investors Should Not Ignore
Agilent (NYSE: A) is poised for strong Q3 2026 earnings on August 26, following a 5.8% EPS beat and raised full-year guidance in Q2. The company boasts superior operating margins compared to competitors like Thermo Fisher and Waters, alongside a robust product cycle fueled by its 9500 ICP-MS launch. Despite a minor Q1 miss attributed to a snowstorm, Agilent's stock has surged, with analysts maintaining a positive outlook.
Portfolio Design Labs LLC Takes $1.53 Million Position in Thermo Fisher Scientific Inc. $TMO
Portfolio Design Labs LLC has acquired a new position of 3,046 shares in Thermo Fisher Scientific Inc., valued at approximately $1.53 million, during the second quarter. This move is part of broader institutional interest, with several other firms also adjusting their stakes in the medical research company. Thermo Fisher Scientific has received a "Moderate Buy" consensus rating from analysts, with a target price of $619.41, and recently reported strong quarterly earnings and declared a quarterly dividend.
4,241 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by Silvant Capital Management LLC
Silvant Capital Management LLC recently acquired 4,241 shares of Thermo Fisher Scientific Inc. (NYSE:TMO) valued at approximately $2.13 million. Other institutional investors also initiated positions, bringing total institutional ownership to 89.23%. Despite significant insider selling over the past 90 days, Thermo Fisher reported strong quarterly earnings, beating analyst estimates, and maintains a "Moderate Buy" consensus rating with an average price target of $619.41.
9,112 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Vise Technologies Inc.
Vise Technologies Inc. acquired a new stake of 9,112 shares in Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, valued at approximately $4.57 million. This purchase is part of broader institutional investor activity, with hedge funds and institutional investors collectively owning 89.23% of the company's stock. Despite some insider selling, analysts maintain a "Moderate Buy" rating for TMO, with a consensus price target of $619.41, following strong quarterly earnings and a 10.5% revenue increase year-over-year.
Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED)
Elon Musk has stated that mRNA technology holds "tremendous" potential for curing diseases, viewing it as a shift that makes medicine more of a software problem. His comments followed an announcement from Moderna and Merck & Co Inc. of positive Phase 3 results for an individualized mRNA cancer vaccine, demonstrating significant improvements in melanoma patients. Despite its potential, Moderna's stock (MRNA) fell over 11% in premarket trading after the news, while other mRNA-focused companies like BioNTech SE and Arcturus Therapeutics Holdings Inc. saw gains.
6,477 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by one8zero8 LLC
one8zero8 LLC recently acquired a new stake of 6,477 shares in Thermo Fisher Scientific Inc. (NYSE:TMO) for approximately $3.25 million during the second quarter. Other institutional investors have also adjusted their holdings, with hedge funds and institutional investors collectively owning 89.23% of the company's stock. The article also notes recent insider stock sales, analyst ratings, financial performance, and a declared quarterly dividend.
A Christian Is Suing His Employer over Fossil Fuels in His 401(k). Does He Have a Case?
A Christian employee, Andrew Hartley, is suing his employer, Thermo Fisher Scientific, for not offering a fossil fuel-free retirement plan, arguing it violates his religious beliefs regarding creation care. The lawsuit is based on a 2023 Supreme Court decision that mandates employers provide religious accommodations unless it incurs "substantial increased costs." If successful, this case could establish a new precedent, allowing employees nationwide to access retirement plans aligned with their faith.
2,646 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by Csenge Advisory Group
Csenge Advisory Group has acquired 2,646 shares of Thermo Fisher Scientific Inc. (NYSE:TMO) valued at approximately $1.33 million. This comes as the company exceeded quarterly expectations with adjusted EPS of $6.03 and revenue of $11.99 billion, representing a 10.5% year-over-year increase. Analysts currently rate the stock as a "Moderate Buy" with an average price target of $619.41, despite recent insider selling of 63,493 shares totaling $37.7 million.
Ceredex Value Advisors LLC Takes Position in Thermo Fisher Scientific Inc. $TMO
Ceredex Value Advisors LLC has acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) by purchasing 51,619 shares valued at approximately $25.88 million. This move is part of broader institutional investor activity, with other firms also adjusting their stakes in the medical research company. Thermo Fisher Scientific recently reported strong Q2 earnings, beating analyst estimates, and declared a quarterly dividend.
Thermo Fisher (TMO) Insider Sell: Sr. VP and Chief HR Officer Li
Lisa Britt, Senior Vice President and Chief Human Resources Officer of Thermo Fisher Scientific (TMO), sold 11,440 shares on August 19, 2026, for approximately $7.01 million. This transaction continues a trend of 26 insider sells and zero insider buys at the company over the past year. While Thermo Fisher is considered "Fairly Valued" according to GuruFocus's GF Value, the consistent insider selling contrasts with significant guru ownership, presenting a mixed signal for investors.
CM Wealth Advisors LLC Buys New Position in Thermo Fisher Scientific Inc. $TMO
CM Wealth Advisors LLC has initiated a new position in Thermo Fisher Scientific Inc. (NYSE:TMO), acquiring 1,693 shares valued at approximately $850,000. Other institutional investors also adjusted their holdings, with Vanguard Group and J. Stern & Co. LLP significantly increasing their stakes. Thermo Fisher Scientific recently reported strong quarterly earnings, beating estimates with $6.03 per share and a 10.5% year-over-year revenue increase, leading to a "Moderate Buy" consensus rating from analysts, despite some recent insider stock sales.
Bank of New York Mellon Corp Invests $1.97 Billion in Thermo Fisher Scientific Inc. $TMO
Bank of New York Mellon Corp has acquired a new stake of 3,938,410 shares in Thermo Fisher Scientific Inc., valued at approximately $1.97 billion, representing 1.07% ownership. Several other institutional investors have also adjusted their holdings in TMO. The article also details recent insider stock sales, analyst rating changes with an average price target of $619.41, and Thermo Fisher Scientific's recent financial performance and dividend declaration.
Advisors Capital Management LLC Makes New Investment in Thermo Fisher Scientific Inc. $TMO
Advisors Capital Management LLC has acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by purchasing 66,082 shares valued at approximately $33.13 million. This new investment is part of broader institutional activity, with other large investors also significantly increasing their holdings in the medical research company. Thermo Fisher Scientific has received a "Moderate Buy" rating from analysts, with a consensus price target of $619.41, and recently reported strong quarterly earnings, beating analyst expectations.
Advisors Preferred LLC Acquires New Holdings in Thermo Fisher Scientific Inc. $TMO
Advisors Preferred LLC has acquired a new position of 3,100 shares, valued at approximately $1,623,000, in Thermo Fisher Scientific Inc. during the second quarter. Several other institutional investors also increased their holdings, and 89.23% of the stock is currently owned by institutional investors. Insider selling activity was noted from COO Gianluca Pettiti and CEO Marc N. Casper, while analysts have issued various ratings, with a consensus of "Moderate Buy" and a target price of $619.41.
Marc Casper lines up another Thermo Fisher (NYSE: TMO) stock sale
Marc N. Casper, an executive at Thermo Fisher Scientific Inc. (TMO), plans to sell 10,000 shares of common stock through a Rule 144 filing, following a stock option exercise on August 20, 2026. This proposed sale has an aggregate market value of $6.29 million and comes after several prior sales by Casper and Floral Park Associates Inc. over the last three months. The filing details these past transactions and highlights Casper's relationship as an authorized individual and stakeholder in Floral Park Associates Inc.
Stryker Corp Stock (SYK) Closed Down by 3.61% on Aug 20: A Full Analysis
Stryker Corp (SYK) stock closed down by 3.61% on August 20, experiencing profit-taking despite a recent U.S. defense contract modification. Investors remain concerned about operational disruptions, cyber incident costs, supply chain bottlenecks, and the company's ambitious second-half revenue guidance. Despite strong fundamentals and analyst consensus, short-term trading dynamics are influenced by macro-level sector rotations and valuation reassessments.
Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market
Thermo Fisher Scientific Inc. (TMO) stock increased by 2.28% on Thursday, closing at $627.55. This performance occurred despite a broader market downturn, with the S&P 500 Index and Dow Jones Industrial Average both experiencing declines. The rise marked the third consecutive day of gains for Thermo Fisher Scientific.
Thermo Fisher (TMO) HR leader exercises options, sells stock
Lisa P. Britt, Senior VP and Chief HR Officer at Thermo Fisher Scientific Inc. (TMO), exercised stock options for 11,440 shares and simultaneously sold all these shares on August 19, 2026. The options were exercised at $418.32 per share, and the shares were sold at a weighted average price of $613.12 per share, resulting in an approximate pre-tax spread of $2.23 million. After the transaction, she directly holds 14,784.148 shares of common stock.
Intuitive Surgical Inc Stock (ISRG) Moved Down by 4.89% on Aug 20: What Signal Does It Send?
Intuitive Surgical Inc (ISRG) stock fell by 4.89% due to concerns over increasing competition in the robotic-assisted surgery market, regulatory clearances for rival systems, and a cautious full-year guidance despite strong operational metrics. Wall Street analysts also revised price targets downward, reflecting hospital capital expenditure caution and broader market anxieties. Technical indicators show a mix of buy, neutral, and sell signals, with low media attention and generally bullish market sentiment.
Kentucky Farm Bureau Mutual Insurance Co Takes Position in Thermo Fisher Scientific Inc. $TMO
Kentucky Farm Bureau Mutual Insurance Co has acquired a new stake of 7,000 shares in Thermo Fisher Scientific Inc. valued at approximately $3.51 million during the second quarter. Other institutional investors also adjusted their holdings in the medical research company. Wall Street analysts have issued a "Moderate Buy" consensus rating for Thermo Fisher Scientific, with a consensus price target of $619.41.
Knuff & Co LLC Acquires Shares of 7,033 Thermo Fisher Scientific Inc. $TMO
Knuff & Co LLC has acquired 7,033 shares of Thermo Fisher Scientific Inc. (NYSE:TMO) valued at approximately $3.53 million during the second quarter. Institutional investors now own 89.23% of the company's stock, and analysts maintain a "Moderate Buy" rating with an average price target of $619.41. Thermo Fisher Scientific exceeded quarterly expectations with $6.03 EPS and $11.99 billion in revenue, also declaring a $0.47 per share quarterly dividend.
Meeder Advisory Services Inc. Acquires Shares of 8,015 Thermo Fisher Scientific Inc. $TMO
Meeder Advisory Services Inc. recently acquired 8,015 shares of Thermo Fisher Scientific Inc., valued at approximately $4.02 million, bringing institutional ownership in the company to 89.23%. Despite recent insider selling, Thermo Fisher reported strong quarterly earnings and revenue, exceeding analyst expectations. The company maintains a "Moderate Buy" consensus rating from analysts, with shares recently trading up 4.3% and a declared quarterly dividend of $0.47 per share.
Wealthfront Advisers LLC Buys Shares of 25,833 Thermo Fisher Scientific Inc. $TMO
Wealthfront Advisers LLC has acquired a new stake of 25,833 shares in Thermo Fisher Scientific Inc. (NYSE:TMO), valued at approximately $12.95 million during the second quarter. Other institutional investors have also adjusted their positions in the company, which has received a "Moderate Buy" consensus rating from analysts with an average target price of $619.41. The company recently reported strong earnings, exceeding analyst expectations, and declared a quarterly dividend of $0.47 per share.
Thermo Fisher Scientific (TMO) Climbed, So What Is Behind The Fresh Attention?
Thermo Fisher Scientific (TMO) has seen increased attention after exceeding analyst expectations with its latest quarterly revenue and earnings, and completing a Parkinson's proteomics project. This strong performance has led to a 16.6% share price return over the past 30 days and a 24.5% total shareholder return over the past year. While some valuations suggest the stock is slightly overvalued, a Discounted Cash Flow model by Simply Wall St indicates it might be modestly undervalued, prompting investors to consider both the optimistic outlook and potential risks.
Flossbach Von Storch SE Takes $955.58 Million Position in Thermo Fisher Scientific Inc. $TMO
Flossbach Von Storch SE has acquired a new stake worth $955.58 million in Thermo Fisher Scientific Inc. during the second quarter, making it their 7th largest holding. Other institutional investors like Vanguard Group Inc., J. Stern & Co. LLP, and BlackRock Inc. have also significantly adjusted their positions in the medical research company. Thermo Fisher Scientific recently reported strong Q2 earnings, beating analyst estimates, and announced a quarterly dividend.
Great Lakes Advisors LLC Invests $7.08 Million in Thermo Fisher Scientific Inc. $TMO
Great Lakes Advisors LLC has invested $7.08 million in Thermo Fisher Scientific Inc. by purchasing 14,113 shares during the second quarter, making them one of many institutional investors holding 89.23% of the company's stock. Thermo Fisher Scientific recently reported strong quarterly results, exceeding analyst expectations with adjusted EPS of $6.03 and revenue of $11.99 billion. Analysts maintain a "Moderate Buy" rating for the company, despite recent insider sales totaling over $30.6 million.
Danske Bank A S Makes New $120.78 Million Investment in Thermo Fisher Scientific Inc. $TMO
Danske Bank A S has acquired a new stake worth $120.78 million in Thermo Fisher Scientific Inc. during the second quarter. Other institutional investors have also adjusted their holdings, while company insiders recently sold shares totaling over $30 million. Thermo Fisher Scientific reported strong earnings, topping analyst estimates, and announced a quarterly dividend, with analysts maintaining a "Moderate Buy" consensus rating for the stock.
Great Lakes Advisors LLC Takes Position in Thermo Fisher Scientific Inc. $TMO
Great Lakes Advisors LLC has acquired a significant new position in Thermo Fisher Scientific Inc. (NYSE:TMO), purchasing 189,606 shares valued at approximately $95.1 million in the second quarter, bringing institutional ownership to 89.23%. This move comes as Thermo Fisher reported strong quarterly earnings, beating EPS estimates and seeing revenue growth of 10.5%. Analysts maintain a "Moderate Buy" rating for the company with an average price target of $619.41, despite recent insider share sales.
Danica Pension Livsforsikringsaktieselskab Invests $46.34 Million in Thermo Fisher Scientific Inc. $TMO
Danica Pension Livsforsikringsaktieselskab recently acquired a new position of 92,429 shares in Thermo Fisher Scientific Inc. (NYSE:TMO) worth approximately $46.34 million during the second quarter. Other institutional investors have also adjusted their holdings in the company. Analysts currently have a "Moderate Buy" consensus rating for TMO with a target price of $619.41, despite some recent target price adjustments.
Great Lakes Advisors LLC Takes $5.64 Million Position in Thermo Fisher Scientific Inc. $TMO
Great Lakes Advisors LLC has acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) by purchasing 11,255 shares worth approximately $5.64 million during the second quarter. This move comes as institutional investors collectively own 89.23% of the company, and Thermo Fisher Scientific recently reported strong quarterly earnings of $6.03 per share, surpassing estimates, with revenue increasing 10.5% year-over-year. Despite a recent downgrade from HSBC, the company maintains a "Moderate Buy" consensus rating among analysts with an average price target of $619.41.
Gables Capital Management Inc. Invests $1.67 Million in Thermo Fisher Scientific Inc. $TMO
Gables Capital Management Inc. has acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) by purchasing 3,326 shares valued at approximately $1.67 million during the second quarter. Other institutional investors have also adjusted their holdings in the company. Analyst ratings for Thermo Fisher Scientific are predominantly "Buy" or "Strong Buy," with an average price target of $619.41, despite recent insider stock sales totaling over $30 million.
Element Pointe Advisors LLC Invests $836,000 in Thermo Fisher Scientific Inc. $TMO
Element Pointe Advisors LLC acquired a new stake of 1,668 shares, valued at $836,000, in Thermo Fisher Scientific Inc. during the second quarter. Other institutional investors have also increased their holdings, with BlackRock Inc. buying a significant new position worth over $15 billion. The company reported strong quarterly earnings, beating analyst estimates, and has declared a quarterly dividend.
First National Bank of Omaha Buys New Position in Thermo Fisher Scientific Inc. $TMO
First National Bank of Omaha has acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO), purchasing 27,553 shares valued at approximately $13.895 million. This move is part of broader institutional interest, with several other firms also adjusting their stakes in the medical research company. Thermo Fisher Scientific recently reported strong quarterly earnings, beating analyst estimates, and has declared a quarterly dividend.
Foster & Motley Inc. Makes New $2.24 Million Investment in Thermo Fisher Scientific Inc. $TMO
Foster & Motley Inc. has acquired a new stake in Thermo Fisher Scientific Inc. valued at approximately $2.24 million, purchasing 4,475 shares during the second quarter. Other institutional investors have also adjusted their holdings in the medical research company, which currently has a "Moderate Buy" rating and a consensus price target of $619.41 from analysts. Additionally, company insiders, including CAO Joseph R. Holmes and CEO Marc N. Casper, have sold shares in recent transactions.
Ripple Holds Above $1 as Solana Gains and Cardano Pauses
Major altcoins like Ripple (XRP), Solana (SOL), and Cardano (ADA) are showing mixed performance after a recent market rebound influenced by US Treasury bond buybacks. XRP holds above $1 with positive short-term indicators but faces resistance from longer-term moving averages. Solana maintains a strong uptrend with robust momentum, while Cardano pulls back, testing support levels despite prior gains.
3,366 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by BOK Financial Private Wealth Inc.
BOK Financial Private Wealth Inc. acquired 3,366 shares of Thermo Fisher Scientific Inc. (NYSE:TMO) for approximately $1.69 million in the second quarter. Institutional investors and hedge funds own 89.23% of the company, which recently reported strong quarterly earnings with $6.03 EPS and $11.99 billion in revenue. Analysts currently maintain a "Moderate Buy" consensus rating for Thermo Fisher Scientific, with an average price target of $619.41.
2,463 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Alpine Woods Capital Investors LLC
Alpine Woods Capital Investors LLC recently purchased 2,463 shares of Thermo Fisher Scientific (NYSE:TMO) valued at approximately $1.24 million in the second quarter. Other institutional investors have also adjusted their holdings in the company, with institutional investors and hedge funds collectively owning 89.23% of the stock. Despite some insider selling, analysts maintain a "Moderate Buy" rating for TMO with a consensus target price of $619.41, following a strong quarterly earnings report that exceeded estimates.
Out of sight, out of work? What’s driving remote job cuts
Some biopharma companies are reducing their remote workforce, forcing employees to choose between returning to the office, relocating, or resigning, as seen with EMD Serono and Exelixis. While many employers cite collaboration benefits for requiring on-site presence, other factors like program cuts or cost reductions also drive layoffs, affecting both remote and on-site staff. Experts suggest that job security remains a general industry risk, regardless of work location, though some candidates are wary of changing remote work policies.
Danaher (DHR) Stock Looks Fairly Valued On Its 23% Five Year Slide
Danaher (DHR) stock has seen a 23.5% decline over the past five years, leading to questions about its valuation. While a Discounted Cash Flow (DCF) model suggests the stock is modestly undervalued by about 7.6%, traditional market multiples, particularly the P/E ratio of 37.3x, indicate it is trading at a premium compared to industry peers and its tailored fair P/E of 29.0x. The article concludes that the stock's current price requires strong future earnings and margin growth to justify its valuation.
Thermo Fisher Scientific Inc. stock rises Wednesday, outperforms market
Shares of Thermo Fisher Scientific Inc. (TMO) rose 4.16% on Wednesday, closing at $613.54. This increase outperformed the broader market, as the S&P 500 Index (SPX) gained 0.21% and the Dow Jones Industrial Average (DJIA) rose 0.22%. This marks the second consecutive day of gains for the stock.
Danaher Corp Stock (DHR) Closed Up by 6.16% on Aug 19: A Full Analysis
Danaher Corp (DHR) stock rose by 6.16% on August 19, driven by strong institutional confidence following positive quarterly earnings and the appointment of Julie Sawyer Montgomery as the new CEO. The company's revenue and adjusted earnings surpassed Wall Street estimates, and its strategic execution, including the Masimo Corporation acquisition, contributed to its upward momentum. Despite some technical indicators suggesting neutrality or a sell condition, fundamental analysis highlights solid financial performance and favorable analyst ratings.
Thermo Fisher (NYSE: TMO) exec plans stock sale after $3.4M trade
A Thermo Fisher Scientific (TMO) officer, Lisa P. Britt, has filed a Rule 144 notice to sell up to 11,440 shares of common stock, valued at approximately $7.01 million, through Fidelity Brokerage Services LLC. This planned sale follows a previous transaction within the last three months where Britt sold 5,850 shares for $3.39 million. The shares being sold were acquired via a stock option exercise and are part of a regulatory filing that includes detailed financial figures and definitions of relevant terms.
Thermo Fisher Scientific Inc Stock (TMO) Moved Up by 3.67% on Aug 19: Facts Behind the Movement
Thermo Fisher Scientific Inc. (TMO) saw its stock rise by 3.67% on August 19, driven by strong Q2 financial results, strategic portfolio optimization including the sale of its microbiology business, and significant institutional investor interest. The company outperformed its sector, with analysts maintaining a largely bullish consensus. Despite technical indicators showing mixed signals and some insider sales, the overall sentiment remains positive due to improving end-market demand and sound execution.
Resmed Inc Stock (RMD) Moved Up by 3.43% on Aug 19: What Investors Need To Know
Resmed Inc (RMD) saw its stock price increase by 3.43% due to positive investor sentiment surrounding capital allocation milestones, increased dividends, and the divestiture of its MatrixCare business. Technical indicators like MACD and Williams %R suggest a buy signal, while fundamental analysis highlights its solid annual revenue and net profit within the Healthcare Services & Equipment industry. Despite some company-specific risks like ventilator product recalls and market share erosion, investor confidence is bolstered by the company's strategic realignments and resilient core demand for sleep apnea devices.
Here's How Abbott's Medical Devices Arm Acts as a Growth Catalyst
Abbott Laboratories' Medical Devices segment is a primary growth driver, fueled by advancements in electrophysiology, increasing adoption of cardiovascular technologies, and the long-term potential of continuous glucose monitoring (CGM). The company is launching new products like the Volt PFA catheter and Libre Duo for glucose and ketone monitoring, and has a strong cardiovascular pipeline extending to 2029 and beyond. Despite this, Abbott's stock has underperformed the industry and currently trades at a higher valuation.
Here's How Abbott's Medical Devices Arm Acts as a Growth Catalyst
Abbott Laboratories' Medical Devices segment is a key growth driver, propelled by advancements in electrophysiology, widespread adoption of cardiovascular technologies, and the significant long-term potential of continuous glucose monitoring (CGM). The company is launching next-generation products like the Volt PFA catheter and Libre Duo, while also developing a robust cardiovascular pipeline extending into 2029 and beyond. Despite these growth catalysts, ABT shares have declined in the past year, and the stock trades at a higher Price-to-Sales multiple compared to the industry median.
Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
Hematogenix announced that its proprietary Next Generation Flow Cytometry (NGF) assay for Multiple Myeloma Minimal Residual Disease (MM MRD) was crucial in the FDA's accelerated approval of Bristol Myers Squibb's ZENBEXUS™ (iberdomide), the first approved CELMoD therapy for multiple myeloma. The assay measured the primary efficacy endpoint of MRD-negative complete response in the EXCALIBER-RRMM trial, highlighting Hematogenix's expertise in registrational oncology trials. This approval reinforces the growing importance of MRD negativity as a measure of treatment success in multiple myeloma and validates Hematogenix's specialized assay methodology.
2,901 Shares in Thermo Fisher Scientific Inc. $TMO Bought by MidFirst Bank
MidFirst Bank acquired 2,901 shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, valuing the new stake at approximately $1.45 million. This purchase is part of broader institutional investment, with various hedge funds also adjusting their positions in TMO, while company insiders have sold over 52,000 shares in the last quarter. Thermo Fisher reported strong Q2 earnings, beating estimates with $6.03 EPS and 10.5% revenue growth, and analysts maintain a "Moderate Buy" rating with a target price of $619.41.
33,810 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by UNIVEST FINANCIAL Corp
UNIVEST FINANCIAL Corp has acquired 33,810 shares of Thermo Fisher Scientific Inc. (NYSE:TMO), valued at approximately $16.95 million, making it their 24th-largest holding. The medical research company reported strong quarterly earnings, beating analyst estimates, and has an average "Moderate Buy" rating from analysts with a target price of $619.41. Despite insider selling activity, institutional investors collectively own 89.23% of the company's stock.
